Skip to main content

Table 1 Baseline disease and demographic characteristics in analysis population

From: Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

  Angiotensin II > 5 ng kg−1 min−1 (n = 84) Angiotensin II ≤ 5 ng kg−1 min−1 (n = 79)
Age, n (%)
 < 65 years 47 (56.0) 43 (54.4)
 ≥ 65 years 37 (44.0) 36 (45.6)
Sex, n (%)
 Male 47 (56.0) 45 (57.0)
 Female 37 (44.0) 34 (43.0)
Race, n (%)
 White 69 (82.1) 66 (83.5)
 Nonwhite 15 (17.9) 13 (16.5)
Body mass index, n (%) n = 83 n = 78
 < 18.5 kg/m2 3 (3.6) 4 (5.1)
 ≥ 18.5 to < 25 kg/m2 22 (26.5) 21 (26.9)
 ≥ 25 to < 30 kg/m2 20 (24.1) 22 (28.2)
 ≥ 30 kg/m2 38 (45.8) 31 (39.7)
Geographic region, n (%)
 Australia/New Zealand 17 (20.2) 11 (13.9)
 Europe 10 (11.9) 9 (11.4)
 USA/Canada 57 (67.9) 59 (74.7)
Albumin, n (%) n = 78 n = 76
 < 2.5 g/dL 56 (71.8) 47 (61.8)
 ≥ 2.5 g/dL 22 (28.2) 29 (38.2)
Cause of shock, n (%)
 Sepsis 68 (81.0) 59 (74.7)
 Likely sepsis 8 (9.5) 12 (15.2)
 Vasoplegia 3 (3.6) 7 (8.9)
 Other 5 (6.0) 1 (1.3)
Baseline MAP,* n (%)   
 < 65 mmHg 37 (44.0) 15 (19.0)
 ≥ 65 mmHg 47 (56.0) 64 (81.0)
Baseline APACHE II score, n (%)
 ≤ 30 54 (64.3) 51 (64.6)
 31–40 29 (34.5) 21 (26.6)
 ≥ 41 1 (1.2) 7 (8.9)
Norepinephrine-equivalent dose 6 h before randomization, mean, µg/kg/min (SD) 0.52 (0.301) 0.45 (0.377)
Baseline norepinephrine-equivalent dose,* n (%)
 < 0.5 µg/kg/min 50 (59.5) 67 (84.8)
 ≥ 0.5 µg/kg/min 34 (40.5) 12 (15.2)
Baseline angiotensin I,* n (%) n = 74 n = 71
 Mean (SD) 678.9 (810.8) 618.0 (1332.5)
 Median (range) 346.0 (10.5–3730.0) 164 (10.5–9180.0)
  < 72.3 pg/mL 12 (16.2) 24 (33.8)
 72.3 to < 253 pg/mL 14 (18.9) 19 (26.8)
 253 to < 676 pg/mL 25 (33.8) 14 (19.7)
  ≥ 676 pg/mL 23 (31.1) 14 (19.7)
Baseline angiotensin II,* n (%) n = 74 n = 70
 Mean (SD) 420.8 (680.3) 128.3 (199.1)
 Median (range) 157.5 (10.5–3340.0) 61.3 (10.5–1090.0)
 < 23.85 pg/mL 14 (18.9) 21 (30.0)
 23.85 to < 83.75 pg/mL 11 (14.9) 21 (30.0)
 83.75 to < 299.5 pg/mL 25 (33.8) 21 (30.0)
 ≥ 299.5 pg/mL 24 (32.4) 7 (10.0)
Exposure to angiotensin-converting enzyme inhibitors 7 (8.3) 8 (10.1)
Exposure to angiotensin II receptor blockers 9 (10.7) 2 (2.5)
Radiographic finding of ARDS 23 (27.4) 17 (21.5)
Cardiac index (L/min/m2) n = 36 n = 33
 Mean (SD) 3.5 (1.07) 3.1 (0.73)
 Median (range) 3.1 (2.3–6.4) 3.0 (2.1–5.4)
ScvO2 (%) n = 59 n = 61
 Mean (SD) 78.2 (8.14) 77 (9.64)
 Median (range) 79.0 (53–99) 75.9 (45–99)
Central venous pressure (mmHg) n = 64 n = 62
 Mean (SD) 14.3 (5.8) 13.2 (4.1)
 Median (range) 13.0 (5–35) 12.0 (6–29)
SOFA score
 Mean (SD) 12.0 (2.8) 11.5 (2.8)
 Median (range) 12.0 (5–18) 12.0 (5–18)
  1. ARDS, acute respiratory distress syndrome; MAP, mean arterial pressure; ScvO2, central venous oxygen saturation; SD, standard deviation; SOFA, Sequential Organ Failure Assessment
  2. All n’s are as in the table header, unless otherwise specified
  3. Exposure to angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers within week prior to starting study
  4. *Statistically significant, P < 0.01